PMID- 35818814
OWN - NLM
STAT- MEDLINE
DCOM- 20220926
LR  - 20220926
IS  - 0301-0430 (Print)
IS  - 0301-0430 (Linking)
VI  - 98
IP  - 3
DP  - 2022 Sep
TI  - Long-term prognosis of monoclonal immunoglobulin-associated glomerular diseases 
      with non-organized deposits: A report of 38 cases from a Japanese single center.
PG  - 135-145
LID - 10.5414/CN110865 [doi]
AB  - Monoclonal immunoglobulin (MIg)-associated glomerular diseases with non-organized 
      deposits are rare disorders. They have recently been categorized into light chain 
      deposit disease (LCDD), light and heavy chain deposit disease (LHCDD), heavy 
      chain deposit disease (HCDD), proliferative glomerulonephritis with MIg deposits 
      (PGNMID) and its light chain only variant (PGNMID-LC), and membranous 
      glomerulopathy with light chain-restricted deposits (MG-LC). In our Japanese 
      cohort of more than 9,500 patients who underwent renal biopsy (1979 - 2020), we 
      evaluated clinicopathological features and long-term outcomes in 38 patients with 
      MIg-associated glomerular diseases with non-organized deposits: LCDD (n = 9), 
      LHCDD (n = 8), HCDD (n = 5), PGNMID-membranoproliferative glomerulonephritis 
      (MPGN) (n = 7), PGNMID-LC (n = 2), and MG-LC (n = 7). In patients with LCDD, a 
      low estimated glomerular filtration rate (eGFR) at biopsy, a high detection rate 
      of urinary MIgs, a high incidence rate of multiple myeloma, and sever 
      tubulointerstitial and vascular lesions were significant clinicopathological 
      characteristics. Median duration of follow-up in each group was 42 - 114 months. 
      Most patients were treated with steroid-based therapy. Patients with LCDD, LHCDD, 
      HCDD, and MG-LC were recently treated with bortezomib-based therapy. Renal 
      survival rate was significantly shorter for LCDD than of PGNMID and MG-LC. 
      Patient survival rate was significantly longer for MG-LC than HCDD and PGNMID. 
      Major causes of death were pulmonary and cardiovascular complications. Among 
      disease groups, significant differences were observed in eGFR at biopsy, 
      detection rates of urinary MIgs, incidence rates of multiple myeloma, severities 
      of tubulointerstitial and vascular lesions, and long-term outcomes.
FAU - Nara, Mizuho
AU  - Nara M
FAU - Komatsuda, Atsushi
AU  - Komatsuda A
FAU - Sawamura, Masato
AU  - Sawamura M
FAU - Abe, Fumito
AU  - Abe F
FAU - Kaga, Hajime
AU  - Kaga H
FAU - Saito, Ayano
AU  - Saito A
FAU - Saito, Masaya
AU  - Saito M
FAU - Imaizumi, Chihiro
AU  - Imaizumi C
FAU - Nanjo, Hiroshi
AU  - Nanjo H
FAU - Wakui, Hideki
AU  - Wakui H
FAU - Takahashi, Naoto
AU  - Takahashi N
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Nephrol
JT  - Clinical nephrology
JID - 0364441
RN  - 0 (Polychlorinated Dibenzodioxins)
RN  - 0 (Steroids)
RN  - 69G8BD63PP (Bortezomib)
RN  - MM6333103R (1,2,3,4,6,7,8-heptachlorodibenzodioxin)
SB  - IM
MH  - Bortezomib
MH  - *Glomerulonephritis/complications/diagnosis/drug therapy
MH  - *Glomerulonephritis, Membranoproliferative/pathology
MH  - Humans
MH  - Japan/epidemiology
MH  - *Kidney Diseases/pathology
MH  - *Multiple Myeloma/complications
MH  - Polychlorinated Dibenzodioxins
MH  - Prognosis
MH  - Steroids
EDAT- 2022/07/13 06:00
MHDA- 2022/09/28 06:00
CRDT- 2022/07/12 03:52
PHST- 2022/08/11 00:00 [accepted]
PHST- 2022/07/13 06:00 [pubmed]
PHST- 2022/09/28 06:00 [medline]
PHST- 2022/07/12 03:52 [entrez]
AID - 189588 [pii]
AID - 10.5414/CN110865 [doi]
PST - ppublish
SO  - Clin Nephrol. 2022 Sep;98(3):135-145. doi: 10.5414/CN110865.